SANDOZ CEFTRIAXONE POWDER FOR SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Tilgjengelig fra:

SANDOZ CANADA INCORPORATED

ATC-kode:

J01DD04

INN (International Name):

CEFTRIAXONE

Dosering :

2G

Legemiddelform:

POWDER FOR SOLUTION

Sammensetning:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2G

Administreringsrute:

INTRAMUSCULAR

Enheter i pakken:

100

Resept typen:

Prescription

Terapeutisk område:

THIRD GENERATION CEPHALOSPORINS

Produkt oppsummering:

Active ingredient group (AIG) number: 0117292002; AHFS:

Autorisasjon status:

CANCELLED PRE MARKET

Autorisasjon dato:

2018-08-01

Preparatomtale

_ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................